Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 189,772,981	$ 30,133,213
Accounts receivable	3,168,578	327,375
Prepaid expenses	1,550,437	1,267,717
Other current assets	478,310	640,117
Short term investments	53,980,307	46,400,176
TOTAL CURRENT ASSETS	248,950,613	78,768,598
Property and equipment, net	13,920,667	13,935,425
Intangible assets, net	18,338,903	18,764,010
Long term investments	59,595,287
Other assets	141,918	141,918
TOTAL ASSETS	340,947,388	111,609,951
CURRENT LIABILITIES
Accounts payable	3,936,590	2,806,098
Accrued expenses	3,907,515	5,043,087
Accrued payroll and benefits	1,629,871	3,937,605
Deferred rent	212,159	307,334
Deferred revenue	124,925,638	600
Note Payable		223,820
Other current liabilities		46,407
TOTAL CURRENT LIABILITIES	134,611,773	12,364,951
LONG-TERM LIABILITIES
Deferred rent, net of current portion	1,664,182	1,702,801
Deferred revenue, net of current portion	33,171,402
Note Payable, net of current portion		2,101,198
Other non-current liabilities		200,000
TOTAL LONG-TERM LIABILITIES	34,835,584	4,003,999
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Common stock, $0.001 par value; 145,000,000 shares authorized; 92,591,457 and 88,505,302 shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	184,961	180,875
Additional paid-in capital	647,142,565	582,902,694
Accumulated other comprehensive income (loss)	(43,744)	(21,564)
Accumulated deficit	(475,228,563)	(487,265,816)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	172,055,219	95,796,189
Noncontrolling interest	(555,188)	(555,188)
TOTAL STOCKHOLDERS’ EQUITY	171,500,031	95,241,001
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 340,947,388	$ 111,609,951